- Poster presentation
- Open Access
Automated HTS/HCS for antivirals using visual HIV full replication assays
- Jean-Philippe Carralot1,
- Mi-Ri Kim2,
- Philippe Kieffer-Kwon3,
- Sandra Corre3,
- Hwa Pyung Kim4,
- Junwon Kim5,
- Boris Lenseigne6,
- Changbok Lee2,
- Denis Fenistein6,
- Thierry Dorval6,
- Hyunrim Oh2,
- Sungjun Han4,
- Zaesung No5,
- Priscille Brodin1,
- Jonathan Cechetto2,
- Annette Boese3,
- Thierry Christophe2 and
- Peter Sommer3
https://doi.org/10.1186/1742-4690-6-S2-P82
© Carralot et al; licensee BioMed Central Ltd. 2009
- Published: 24 September 2009
Keywords
- Human Immunodeficiency Virus
- Infectious Disease
- Treatment Strategy
- Small Molecule
- Drug Resistance
There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents and treatment strategies are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy and the inability to cure infected individuals. We developed visual, HIV full replication assays and implemented them in high-throughput compound (n = 200.000) and genome-wide siRNA screens, which allowed the identification of a few thousand novel small molecules with potent anti-retroviral activity and a few hundred host factors required for HIV infection, respectively. The identified compounds and host factors are opening unexplored avenues to novel antiviral drug and target discovery and validation, and should feed the drug development pipeline in the near future.
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd.
